PSEUDORABIES VIRUS (PRV) / AUJESZKY'S DISEASE
LEVELS: Rarely occurs: Requires significant failure at one or more control points for transmission to humans; Highly unlikely: No evidence of non-foodborne zoonotic transmission; Highly effective: Routine on-farm biosecurity measures are effective in preventing farm-to-farm transmission; Moderate: Clinical signs not unique but existing tests available at local/regional laboratory(s); Substantial: Unsustainable acute or chronic losses related to severe clinical signs in a high prevalence of animals; Prolonged disruption: Measureable negative effect on demand for more than 6 months when disease occurs on one or more farms; Minimal risk: Agent inherently unlikely to develop clinically important resistance to antibacterial or antiviral treatments; Minimal risk: Antibacterial or antiviral treatments rarely occur, or are typically limited to short-course individual animal therapy; No availability: Effective treatments not currently available in the US (or have not been developed); Widely available: Effective commercial vaccines widely available in the US (or held in national response stockpile); Highly likely: Can be eradicated using existing tools and knowledge
OVERVIEW
Pseudorabies virus (PRV), also known as Aujeszky's disease virus or suid alphaherpesvirus 1 (SuAHV1), is an alphaherpesvirus in the family Orthoherpesviridae that causes one of the most historically significant viral diseases of swine. First described in cattle in 1813 (where it causes fatal neurological disease with intense pruritus, hence "mad itch"), PRV was not recognized in its natural host—domestic pigs—until 1931. Pigs are the only species that can survive productive PRV infection; all other susceptible mammals (cattle, sheep, dogs, cats, wildlife) develop invariably fatal disease. PRV became a major global scourge of pig production in the 1970s-1980s, causing devastating losses through fatal neurological disease in piglets, reproductive failure in sows, and respiratory disease across all ages. The development of gene-deleted "marker" vaccines (DIVA vaccines) in the 1980s revolutionized control, enabling serological differentiation of vaccinated from infected animals and making large-scale eradication economically feasible. PRV has been successfully eradicated from domestic pig populations in the United States (2004), most of Western Europe, Canada, and New Zealand. However, the virus remains endemic in feral swine populations across the southern United States (0.5-61% prevalence) and in wild boar throughout Europe, representing a constant reintroduction threat. Recent emergence of more virulent PRV variants in China since 2011 demonstrates ongoing evolution and the need for continued vigilance.
FOODBORNE ZOONOTIC TRANSMISSION POTENTIAL
Level: Rarely occurs: Requires significant failure at one or more control points for transmission to humans
Human susceptibility to PRV was historically considered negligible, demonstrated through self-inoculation experiments showing resistance to infection. However, recent case reports from China describe natural human PRV infections causing encephalitis and endophthalmitis, primarily in pig farm workers with finger injuries or other skin wounds who had direct contact with infected pigs. A human-origin PRV strain (hSD-1/2019) was isolated from cerebrospinal fluid of infected patients, providing direct evidence of human infection. All documented patients survived with resolution of clinical symptoms, though whether recovered patients harbor latent PRV remains unclear. These cases represent occupational exposure through direct contact rather than foodborne transmission. No foodborne transmission from consumption of pork products has been documented, though PRV remains infectious in meat at refrigeration temperatures and requires heat treatment (80°C) for inactivation.
NON-FOODBORNE ZOONOTIC TRANSMISSION POTENTIAL
Level: Highly unlikely: No evidence of non-foodborne zoonotic transmission
Direct contact transmission to humans has been documented in recent case reports, primarily involving pig farm workers in China with skin injuries who had close contact with PRV-infected pigs. Clinical presentations included encephalitis with fever, headache, seizures, and visual disturbances including endophthalmitis. The route of infection appears to be through skin wounds rather than respiratory exposure. Human infections remain rare despite extensive occupational exposure to PRV over decades of endemic circulation. The recent Chinese cases may reflect increased virulence of emerging PRV variants or improved diagnostic recognition. It is now considered prudent to wear skin protection when in close contact with PRV-infected pigs. Importantly, humans do not transmit PRV to other humans or animals—infected humans are dead-end hosts.
EFFECTIVENESS OF ON-FARM BIOSECURITY IN PREVENTING FARM-TO-FARM TRANSMISSION
Level: Highly effective: Routine on-farm biosecurity measures are effective in preventing farm-to-farm transmission
PRV spreads primarily through direct contact between pigs and contact with contaminated fomites, secretions, and aerosols. The virus is shed in high concentrations in nasal and pharyngeal secretions (up to 10⁶-10⁸ TCID₅₀), with shedding beginning 1-2 days post-infection before clinical signs appear. Airborne transmission occurs within buildings and for short distances outside under favorable conditions, though long-distance airborne spread remains disputed. Standard biosecurity measures are generally effective when rigorously applied—PRV is not highly contagious and requires relatively high infectious doses (>10⁴-10⁵ TCID₅₀) to infect adult animals. However, several factors can bypass biosecurity: (1) feral swine and wild boar populations serve as reservoir hosts that can contact domestic pigs at farm boundaries; (2) latently infected animals shed no virus but can reactivate under stress (transport, farrowing) and resume shedding; (3) dogs, cats, and wildlife (raccoons, rats) can become infected by consuming infected carcasses and briefly shed virus before dying; (4) the virus survives for extended periods on fomites (weeks on straw, concrete, wood) and in slurry (months at low temperatures).
DIFFICULTY OF DETECTING AND CONFIRMING INFECTION
Level: Moderate: Clinical signs not unique but existing tests available at local/regional laboratory(s)
Clinical presentation varies substantially with pig age, making recognition challenging. Neonatal pigs may die suddenly with minimal signs; weaning-age pigs show classic neurological signs (trembling, ataxia, convulsions, paralysis); older pigs develop primarily respiratory disease or subclinical infection. Reproductive failure (abortion, mummification, stillbirth) in sows is not pathognomonic. No gross lesions are specific to PRV—multifocal necrosis in liver, spleen, and tonsils of young piglets are suggestive but require confirmation. Laboratory diagnosis is well-established: virus isolation in multiple cell lines (PK-15, RK-13, Vero) with CPE in 2-5 days; PCR assays targeting gB, gC, gD, or gE genes; immunofluorescence or immunohistochemistry on tissues; and serology (ELISA, virus neutralization). Critically, gE-specific ELISAs differentiate naturally infected (gE-positive) from vaccinated (gE-negative) animals—the foundation of DIVA-based eradication programs. Latent infection can only be detected by PCR for viral DNA in ganglia or by experimental reactivation with corticosteroids.
FINANCIAL IMPACT ON FARM'S COST OF PRODUCTION
Level: Substantial: Unsustainable acute or chronic losses related to severe clinical signs in a high prevalence of animals
PRV causes devastating age-dependent losses. In neonatal piglets less than 7 days old, mortality approaches 100% with sudden death and minimal clinical signs. In 2-3 week old piglets, mortality remains high (up to 100%) with severe neurological disease. Mortality decreases with age: ~50% at 4 weeks, <5% by 5 months, and minimal in adults. However, morbidity remains high across all ages. Reproductive losses include embryonic death and resorption, fetal mummification, abortion storms, and stillbirths—particularly devastating when virus enters a naive breeding herd. Boars develop temporary infertility with abnormal spermatozoa. Growing pigs experience weight loss during clinical disease and are predisposed to secondary bacterial pneumonia. In finishing operations with high pig density, respiratory involvement amplifies and secondary infections increase mortality. During the 1970s-1980s epidemic period, PRV caused sufficient losses to drive development of the first genetically engineered livestock vaccines.
EFFECT ON DOMESTIC OR EXPORT MARKETS
Level: Prolonged disruption: Measureable negative effect on demand for more than 6 months when disease occurs on one or more farms
PRV/Aujeszky's disease is an OIE/WOAH-listed disease with significant trade implications. The United States achieved PRV-free status in domestic swine in 2004 after a multi-decade eradication campaign. Detection of PRV in domestic pigs would immediately trigger regulatory response, movement restrictions, and trade partner concerns. Countries that have achieved PRV-free status prohibit vaccination to maintain serological surveillance capability—any positive serology indicates infection. Reintroduction from feral swine populations remains the primary risk in the US. International trade in pigs and pork products between PRV-free and PRV-endemic regions is heavily regulated. The combination of OIE listing, historical devastation, successful eradication investment, and ongoing feral swine reservoir creates a situation where PRV detection in US domestic pigs would trigger immediate and severe market response despite the availability of effective control tools.
PATHOGEN'S ABILITY TO DEVELOP AND SPREAD RESISTANCE
Level: Minimal risk: Agent inherently unlikely to develop clinically important resistance to antibacterial or antiviral treatments
PRV is a DNA virus (alphaherpesvirus) that does not carry, acquire, or transmit antimicrobial resistance genes. The virus poses no AMR concerns. However, viral evolution remains relevant: emerging PRV variants in China since 2011 show increased virulence in vaccinated herds, potentially through recombination with vaccine strains (Bartha-K61). This represents antigenic/virulence evolution rather than antimicrobial resistance.
AMR DEVELOPMENT DRIVEN BY DISEASE MANAGEMENT
Level: Minimal risk: Antibacterial or antiviral treatments rarely occur, or are typically limited to short-course individual animal therapy
No antiviral treatments exist for PRV. Disease management relies entirely on vaccination and biosecurity/eradication rather than antimicrobial therapy. Antimicrobials may be used to treat secondary bacterial pneumonia in PRV-affected herds, but this represents a minor, short-term use pattern. PRV control programs do not drive significant antimicrobial selection pressure. In eradication programs, affected herds are typically depopulated rather than treated.
AVAILABILITY OF EFFECTIVE TREATMENT OPTIONS
Level: No availability: Effective treatments not currently available in the US (or have not been developed)
No specific antiviral treatments exist for PRV infection. Management is entirely preventive (vaccination, biosecurity) or reactive (depopulation for eradication). Supportive care has limited value given the rapid, severe course in susceptible animals. Recovered pigs remain latently infected for life with potential for reactivation and shedding—"treatment" cannot eliminate the carrier state. Secondary bacterial infections may be treated with antimicrobials, but this does not address the underlying viral disease.
AVAILABILITY OF EFFECTIVE VACCINES OR BACTERINS
Level: Widely available: Effective commercial vaccines widely available in the US (or held in national response stockpile)
PRV vaccines represent a landmark achievement in veterinary vaccinology—the first genetically engineered "marker" (DIVA) vaccines used at scale in livestock. Both inactivated and modified-live vaccines are available, with modified-live vaccines (particularly the Bartha-K61 strain) providing superior efficacy. The Bartha strain carries natural deletions in glycoprotein gE, enabling serological differentiation: vaccinated animals are gE-antibody negative while naturally infected animals are gE-positive. This DIVA capability made cost-effective eradication feasible across large geographic areas. Vaccines effectively prevent clinical disease, reduce virus shedding, and decrease transmission, though they do not prevent infection or establishment of latency by wild-type virus. Precolonization of ganglia by vaccine virus reduces subsequent latency of challenge virus. Maternal antibodies persist 14-15 weeks and interfere with piglet vaccination. Recent concerns about reduced efficacy of classical GIII-based vaccines against emerging Chinese PRV variants have prompted development of updated vaccine candidates, though studies confirm Bartha-K61 vaccines retain efficacy when properly used.
FEASIBILITY OF ERADICATING THE DISEASE FROM THE US
Level: Highly likely: Can be eradicated using existing tools and knowledge
PRV has already been successfully eradicated from US domestic pig populations—the US achieved PRV-free status in 2004 following decades of coordinated effort. The eradication toolkit is well-established: DIVA vaccines combined with gE-differential ELISA testing enable identification and removal of infected animals from vaccinated herds; test-and-removal programs systematically eliminate infected herds; movement controls prevent spread; and surveillance maintains freedom. Similar eradication has been achieved across Western Europe, Canada, and New Zealand. The remaining challenge is the feral swine reservoir—PRV is endemic in feral pig populations across the southern US at prevalences up to 61%. Complete eradication would require elimination or management of feral swine, which presents substantial practical and political challenges. However, maintaining freedom in domestic swine through biosecurity separation from feral populations is achievable with current tools. Reintroduction and re-eradication from domestic herds, should it occur, would follow established protocols.